Safety Study of Rituximab (Rituxan®) in Chronic Urticaria

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT00216762
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Urticaria

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart

Study Details

This study is being done to find out if a drug called Rituxan (Rituximab) is safe and effective in treating people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.

Key Dates

Start date
Jan 31, 2006
Status verified
Aug 2015
Primary completion
May 31, 2007
Completion
May 31, 2007

Study Design

Enrollment
15 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Safety of Rituximab infusions in this patient population [ Time Frame: 1 year or time until reconstitution of B cells ]

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins University, Bayview Medical CenterBaltimoreMaryland21224-

Find similar trials in Baltimore, MD

By research site
Johns Hopkins University, Bayview Medical Center· Baltimore, MD